A preferred dose ranges between 0.05-500 mg/kg, more preferably between 0.5-50 mg/kg.A compound of the invention can be used alone or in combination with other agents that have NOS-inhibiting activity, or in combination with other types of treatment (which may or may not inhibit NOS) to treat, prevent, and/or reduce the risk of stroke, neuropathic or migraine pain, or other disorders that benefit